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Objective: To optimise the indication and time for operation for abdominal aortic aneurysm (AAA), we analysed whether 
or not serum-elastin-peptides (SEP) could be a potential predictor for expansion. 
Materials and methods: Four thousand, four hundred and four 65-73-year-old males were invited for screening to 
detect an AAA. Three thousand, three hundred and thirty-four attended (76%). One hundred and forty-one had AAA, 
and 19>5 cm in diameter were referred for immediate operation. The remaining 122 AAA were offered an annual follow- 
up. Ninety-nine were later asked for a blood-sample, 83 attended. SEP was determined using an ELISA-technique. The 
observer was blinded to the SEP result. 
Results: The average xpansion was 2.6 ram~year, and 10 (8.1%) were referred for operation because of a diameter of 
>5 era. SEP were positively correlated to expansion (R = 0.4, F = 14.65). In multiple regression analyses, AAA size, SEP, 
beta-agonist-treatment, and FEV1, but not beta-blockers, were predictors of expansion. SEP remained a relatively strong 
predictor (F = 13.13). 
Conclusions: Serum-eI~stin-peptides s em to predict expansion, but a larger, longer study is needed to establish clinical 
recommendations. 
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Introduction 
Previous reports have described a 0.0-0.5% annual 
rupture rate of abdominal aortic aneurysms (AAA) 
below 5 cm in diameter, ~-7 while AAA above 5 cm 
found at autopsy have an increased risk of rupture 
with increasing AAA size; from 20-50% of AAAs with 
5-7 cm in diameter to 95% in AAA above 10 cm in 
diameter. 1's'9 These autopsy-reports have been con- 
firmed by clinical studies. 3'5-7'1°-13 Therefore the in- 
dication to operate is determinated by the size of the 
AAA. However, small AAA do occasionally rupture, 
while some operated AAA would never have rup- 
tured. Furthermore, increasing use of ultrasonographic 
scanning, and computed tomography (CT)-scanning, 
have increased the number of small AAA diagnosed. 
Some will expand to a size where surgery is indicated, 
but the patients will then be older with an increased 
risk at operation, or eventually a contraindication for 
operation. Conservative treatment of small AAA may 
create psychological stress among the patients. These 
problems will increase if screening for AAA proves to 
be beneficial. Therefore, more accurate indications for 
operation would be desirable. 
Elastin is a major component of the human ab- 
dominal aorta. In AAA the structure and the amount 
of elastin is alternated, and increased levels of elastase 
have been noticed. 14-17 The measurement of circulating 
elastin peptides has been proposed as a method for 
monitoring of pathological processes involving de- 
gradat ion of elastic tissue as in emphysema. ~8-21 In 
patients with ischaemic heart disease, moderately in- 
creased levels of circulating elastin peptides have been 
found,  22 but there are no previous data on circulating 
elastin peptides in patients with AAA. The aim of our 
study was to see whether serum elastin peptide levels 
could be a possible predictor for the expansion of 
small AAA. 
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Material and Methods 
In 1994, 4404 65-73-year-old men were invi ted to 
screening for AAAs.  B-mode scans were carried out 
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with a small Phillips SDR 1550 with linear 4 mHz 
transducer and calliper light pen. 
An AAA was when the anterioposteriorly aortic 
diameter was 30 mm or more. AAAs of 5 cm or more 
were referred to a vascular surgeon. AAAs of 3-4.9 cm 
were offered yearly follow-up examinations to check 
for any expansion. Present medication and smoking 
habits were recorded. Height and weight were meas- 
ured. The brachial blood-pressure was measured on 
each arm, and the highest pressure was registered. 
The systolic ankle-blood pressure was measured at 
each ankle, and the lowest pressure was registered. 
The forced first second expiratory volume (FEV1) and 
the forced vital capacity (FVC) was measured three 
times with a mobile vitalograph, and the highest vol- 
ume was registered, respectively. Calibration was car- 
ried out before each patient. 
Blood samples were taken within 10 days of the initial 
scan. Only subjects living less than 30 km from the hos- 
pital were asked to participate. Serum was stored at 
-21°C until analysis. The concentration of elastin- 
peptides in serum was determined using an inhibition 
type of enzyme-linked immunosorbent assay (ELISA) 
performed as described by Giro and Davidson. 23 Briefly, 
microtitre plates were coated with human aortic elastin 
(100 ng per well). A standard curve was prepared by 
serial dilution of human aortic elastin 0.1-26 ng per 
well. Purified human aortic elastin peptides and specific 
rabbit antihuman elastin IgG were obtained from 
Elastin Products Company, MO, U.S.A. The antibody 
was raised against alpha-elastin prepared from human 
aorta. 24 Antiserum was diluted 1:500 in phosphate buf- 
fered saline containing 0.1% Tween 20. Binding was 
continued overnight at 4°C. The competition reaction 
was then transferred tothe coated plate and incubated 
for 30 min. Bound antibodies were reacted with per- 
oxidase-goat-antirabbit IgG,diluted 1:1000 for i h. O- 
phenylenediamine substrate was used as a substrate. 
The intra- and interassay coefficients of variation were 
6 and 10%, respectively. Standards and serum-samples 
were analysed in duplicates. 
At the following control-scans, the same scanner 
and observer as at the initial consultation was used. 
The observer was blinded from the results from the 
blood-samples. The trial was approved by the local 
scientific ethics committee and reported to the Central 
Control of Registers. Mann-Whitney tests, bivariate- 
and multiple linear regression analyses were used. 
) 
Results 
Of the 4404 who were invited, 3344 attended (76%) 
and 141 (4.2%) had AAA. Of these, 19 aneurysms 
Table 1. The expansion of small abdominal aortic aneurysms and 
anamnestic informations (dichotomous variables). 
Variable Expansion Mann- 
(yes/no) Whitney 
Arterial hypertension 2.56/2.68 0.59 
Acute myocardial infarction 2.31/2.72 0.62 
Chr. obstructive pulmonary disease 3.57/2.52 0.28 
Intermittent claudication 1.57/2.70 0.37 
Angina pectoris 1.96/2.73 0.26 
Smoking 3.05/1.99 0.15 
Steroid treatment 3.53/2,.56 0.20 
Beta-agonist treatment 4.40/2.47 "0.01 
Beta-blockers 2.08/2.75 0.21 
Expansion: mm pel? year. 
(13.5%) were more than 5 cm, and the patients were 
referred to the department of vascular surgery for 
repair. The remaining 122 patients with a small AAA 
were offered an annual follow-up. Of these, four (3.2%) 
died in the following year, one (0.8%) was acutely 
operated on because of symptoms of rupture, and 
seven (6.4%) did not attend. At follow-up, two (1.8%) 
were shown to be false-positives, and 10 (8.1%) were 
referred for surgery because of expansion to a diameter 
of 5 cm or more. Ninety-nine patients with a small 
AAA were previously asked for a blood sample, 83 
attended blood-sampling. Of these, 79 attended follow- 
up. In order to validate the scans, 24 patients had their 
AAA measured twice with blinded interpretation (95% 
were measured within a difference of 2 mm). 
In Table 1, dichotomous (yes/no) variables are tested 
as predictors of expansion. Beta-agonist-users had more 
rapid expansion than non-beta-agonist-users. Beta- 
blockers, smoking, and steroid-treatment didnot seem 
to influence xpansion. InTable 2, continuous variables 
are tested by bivariate regression-analysis as predictors 
of expansion. Initial AAA-size, as well as serum-elastin- 
peptides were positively correlated with expansion~ 
Table 2. Bivariate linear regression analysis of continuous vari- 
ables and the expansion of small abdominal aortic aneurysms. 
Independent Partial R-coefficient 
variable F-test (95% CI) 
Initial AAA-size 39.4* 0.54 ( 0.37-0.65) 
S-elastin peptides 14.7" 0.40 ( 0.20-0.57) 
Systolic blood pressure 0.01 0.01 (-0.18-0,20) 
Diastolic pressure 1.56 0.12 (-0.07~9.31) 
FEV1 0.56 0.07 ( - 0.12M?.26) 
FVC 0.94 0.10 (-0.10-0.28) 
BMI 0.30 -0.06 (-0.25-0.14) 
Ankle blood pressure 0.73 0.11 (-0.11-0.27) 
ABI 0.67 0:08 (-0.11-0.27) 
ABI = Ankle blood pressure/systolic blood pressure. 
* p<0.05. 
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Fig. 1. S=elastin-peptides and the expansion of small abdominal ortic aneurysms. R= 0.40 (95% CI: 0.20-0.57). 
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Fig. 2. S-elastin-peptides and the size of the small 
Initial AAA size (mm) 
abdominal ortic aneurysm. R=0.14 (95% CI: -0.08-0.34). 
(Fig. 1), but  initial AAA-s ize and elastin-peptides-con- 
centration were not posit ively correlated (Fig. 2). Ankle- 
and brachial b lood pressures, body  mass index, FEV1, 
and FVC did not seem to influence expansion. In Table 
3, the results of a multiple regression analysis are shown 
involv ing some of the variables in Tables i and 2. Yes/ 
no variables were converted to numeric  variables with 
1 and 0 values, respectively. The initial AAA-size,  the 
concentrat ion of serum-elastin-peptides, FEV1, and 
beta-agonist-treatment, all remained independent  pre- 
dictors of expansion. 
Discussion 
Earlier reports have observed increased expansion 
with increasing diastolic b lood pressure, 25'26 and sys- 
tolic ankle blood pressure. 27 We could not confirm 
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Table 3. Multiple linear regression analysis. Annual expansion of 
small abdominal aortic aneurysm as a dependent variable. 
Independent Beta- 95% CI Partial 
variable coefficient F-test 
Initial AAA-size 0.21 0.12-0.29 23.10" 
S-elastin peptides 0.09 0.04-0.14 13.22" 
FEV1 0.01 0.00-0.02 5.89* 
Beta-agonist treatment 2.19 0.23-4.15 4.76* 
Steroid-treatment 1.74 -0.01-3.49 3.80 
Diastolic blood pressure 0.03 -0.01-0.06 2.43 
Smoking 0.11 -0.85-1.06 0.04 
ABI 0.01 -0.02-0.02 0.14 
Beta-blockers -0.55 -1.87-0.78 0.66 
BMI - 0.01 - 0.13-0.11 0.03 
* p<0.05. 
ABI= ankle blood pressure/systolic blood pressure. 
these observations, but diastolic blood pressure tended 
to be positively correlated to expansion. Beta-agonists 
and beta-blockers were analysed because of earlier 
reports of lower expansion among beta-blocker- 
users .  26'28'29 The possible effect of beta-blockers is 
thought to be caused by increased cross-linkage of 
collagen and elastin. 3° Beta-blockers did not influence 
expansion in our study. However, randomised trials 
with propranolol are now under progress in Hun- 
tingdon (U.K.), Canada, and Viborg (Denmark). We 
observed more expansion among beta-agonist-users. 
Steroid-users also tended to have increased expansion, 
and FEV1 were positively correlated to expansion. 
These observations seem to suggest that the increased 
prevalence of AAA among people with chronic ob- 
structive pulmonary disease are more likely to be 
caused by their medication rather than their pul- 
monary disease. 
Despite using the same scanner and observer at the 
initial scan and at follow-up, a measurement variability 
of 2-3 mm must be expected. 31-33 If expansion was 
defined as above 2 or above 3 mm per year, the levels 
of serum-elastin-peptides were significantly higher 
among expanding AAA compared to non-expanding 
AAA (p = 0.004 and p = 0.008, respectively). 
The observation that elastin-peptides remained a 
relatively strong predictor of expansion in the multiple 
regression analysis adjusted for AAA-size suggests a
potential predictor of expanding small AAA. However, 
the presented material is too small to create valid 
predictions that would be usable in clinical practice. 
A larger study with longer follow-up is needed to 
determine whether serum elastin peptides may be 
useful predictors of AAA expansion. 
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